Chang-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton M R, Royer-Pokora B
Deutsches Krebsforschungszentrum, Division of Epidemiology, Heidelberg, Germany.
J Med Genet. 1998 Feb;35(2):116-21. doi: 10.1136/jmg.35.2.116.
Germline mutations in highly penetrant autosomal dominant genes explain about 5% of all breast cancer, and heritable mutations in the BRCA1 breast and ovarian cancer susceptibility gene account for 2-3% of breast cancer in the general population. Nevertheless, the presence of such mutations is highly predictive of disease development. Since screening for mutations is still technically laborious, we investigated whether the prior probability of being a carrier of a dominant breast cancer susceptibility gene in the youngest affected family member could be used to identify families in which the probability of finding a mutation is sufficiently high. Sixty German families with three or more cases of breast/ovarian cancer with at least two cases diagnosed under the age of 60 were screened for mutations by SSCP/CSGE and subsequent direct sequencing. Thirteen germline truncating/splicing mutations in BRCA1 were found in 33% (6/18) of the breast-ovarian cancer families and in 17% (7/42) of breast cancer only families. All the families showing mutations in BRCA1 had carrier probabilities of 0.65 or higher. In families with prior carrier probabilities above 0.6, the proportion detected was 0.46 in breast-ovarian cancer families and 0.26 in breast cancer only families. The average age at diagnosis of breast or ovarian cancer in families with BRCA1 mutations was 41.9 years and significantly lower than in families without mutations (p < 0.05). Mutation carriers and obligate carriers were also found to have cancers at other sites. The probability of being a susceptibility gene carrier, taking into account the complete pedigree information, allows uniform characterisation of all types of families for identifying those in which mutation analysis for BRCA1/2 is warranted. However, prior probabilities calculated using this method can be reduced when the correlation between genotype and phenotype is imperfect. A larger series of families needs to be investigated in this fashion to provide better estimates of the detection rate for different ranges of carrier probabilities.
高外显率常染色体显性基因中的种系突变约占所有乳腺癌病例的5%,而乳腺癌和卵巢癌易感基因BRCA1中的可遗传突变在普通人群的乳腺癌病例中占2% - 3%。然而,此类突变的存在对疾病发展具有高度预测性。由于突变筛查在技术上仍然费力,我们研究了最年轻的受影响家庭成员中成为显性乳腺癌易感基因携带者的先验概率是否可用于识别发现突变概率足够高的家族。对60个有三例或更多乳腺癌/卵巢癌病例且至少两例在60岁之前确诊的德国家族进行了筛查,通过单链构象多态性/恒定变性凝胶电泳(SSCP/CSGE)及后续直接测序来检测突变。在33%(6/18)的乳腺癌 - 卵巢癌家族和17%(7/42)的仅患乳腺癌家族中发现了13种BRCA1种系截短/剪接突变。所有显示BRCA1突变的家族其携带者概率均为0.65或更高。在先验携带者概率高于0.6的家族中,乳腺癌 - 卵巢癌家族的检测比例为0.46,仅患乳腺癌家族的检测比例为0.26。BRCA1突变家族中乳腺癌或卵巢癌的平均诊断年龄为41.9岁,显著低于无突变家族(p < 0.05)。还发现突变携带者和必然携带者在其他部位也患有癌症。考虑完整的系谱信息后,成为易感基因携带者的概率可对所有类型的家族进行统一特征描述,以识别那些有必要进行BRCA1/2突变分析的家族。然而,当基因型与表型之间的相关性不完善时,使用此方法计算的先验概率可能会降低。需要以这种方式研究更多系列的家族,以便为不同携带者概率范围的检测率提供更好的估计。